In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM

摘要: Tumor hypoxia is recognized as an important determinant of response to therapy. In this study we investigated the feasibility clinical imaging with copper-60 diacetyl-bis(N 4-methylthiosemicarbazone) (60Cu-ATSM) in patients non-small-cell lung cancer (NSCLC) and also assessed whether pretreatment tumor uptake 60Cu-ATSM predicts responsiveness Nineteen biopsy-proved NSCLC were studied by positron emission tomography (PET) before initiation was evaluated semiquantitatively determining tumor-to-muscle activity ratio (T/M). All underwent PET fluorine-18 fluorodeoxyglucose (FDG) prior institution The results correlated follow-up evaluation (2–46 months). It demonstrated that NCSLC feasible. one patient had no discernible uptake, whereas remaining variable, expected. Response 14 patients; mean T/M for significantly lower responders (1.5±0.4) than nonresponders (3.4±0.8) (P=0.002). However, SUV not different (2.8±1.1) (3.5±1.0) (P=0.2). An arbitrarily selected threshold 3.0 discriminated those likely respond therapy: all eight a <3.0 six ≥3.0. FDG (P=0.7) did correlate (r=0.04; P=0.9). 60Cu-ATSM-PET can be readily performed reveals clinically unique information about oxygenation predictive